Menu Search
Equities

Cypherpunk Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5MC:STU

Cypherpunk Technologies Inc

Actions
  • Price (EUR)0.51
  • Today's Change-0.055 / -9.73%
  • Shares traded0.00
  • 1 Year change+4.08%
  • Beta-0.1764
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-50.81m
  • Incorporated2011
  • Employees52.00
  • Location
    Cypherpunk Technologies Inc47 Thorndike Street, Suite B1-1CAMBRIDGE 02142United StatesUSA
  • Phone+1 (617) 252-4343
  • Fax+1 (302) 636-5454
  • Websitehttps://www.leaptx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.